Payment overview · 2025
General Payments
$238.32
11 reported records · 5 companies
Healthcare provider profile · identity verified
Lori King, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BUTLER, MO · NPI 1124595699
Verified facts
What the public records show
CMS Open Payments records show Lori King, FNP received $238.32 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 67.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $160.51 | 67.3% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.25 | 12.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.42 | 8.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.57 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.57 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.32 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $160.51 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 64 |
| Gabapentin | Gabapentin | 215 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 204 | 49 |
| Lisinopril | Lisinopril | 200 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 48 |
| Alprazolam | Alprazolam | 162 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 29 |
| Ezetimibe | Ezetimibe | 142 | 34 |
| Glipizide Er | Glipizide | 122 | 23 |
| Metformin Hcl Er | Metformin Hcl | 119 | 22 |
| Metformin Hcl | Metformin Hcl | 113 | 21 |
| Potassium Chloride | Potassium Chloride | 113 | 25 |
| Losartan Potassium | Losartan Potassium | 111 | 22 |
| Sertraline Hcl | Sertraline Hcl | 106 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 17 |
| Omeprazole | Omeprazole | 91 | 26 |
| Simvastatin | Simvastatin | 90 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 19 |
| Farxiga | Dapagliflozin Propanediol | 88 | 14 |
| Montelukast Sodium | Montelukast Sodium | 88 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 32 |
| Meloxicam | Meloxicam | 79 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 12 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 16 |
| Famotidine | Famotidine | 69 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 15 |
| Trazodone Hcl | Trazodone Hcl | 66 | suppressed |
| Furosemide | Furosemide | 65 | 16 |
| Jardiance | Empagliflozin | 63 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 62 | 17 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Fenofibrate | Fenofibrate | 57 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 39 |
| Jantoven | Warfarin Sodium | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Azithromycin | Azithromycin | 42 | 36 |
| Mupirocin | Mupirocin | 40 | 25 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Olanzapine | Olanzapine | 39 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Prednisone | Prednisone | 29 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 11 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.32 · 11 records | Otsuka America Pharmaceutical, Inc. | CAPLYTA, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error